TMO
Thermo Fisher Scientific Inc. · Healthcare
Insiders sold $133.0M of Thermo Fisher Scientific Inc. in the last 12 months and bought none
TMO over the last year
TMO after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Congress
Members reported 103 trades in TMO since 2023.
Every filing
201 insider filings since 2016, newest first
Marc N Casper · Chair and CEO
Gianluca Pettiti · EVP
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Stephen Williamson · SVP and CFO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Jim P Manzi · Director
Debora L Spar · Director
Gianluca Pettiti · EVP
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Stephen Williamson · SVP and CFO
Michael A Boxer · SVP and General Counsel
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Jim P Manzi · Director
Michel Lagarde · EVP and COO
Michel Lagarde · EVP and COO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Debora L Spar · Director
Marc N Casper · Chair and CEO
Michel Lagarde · EVP and COO
Jim P Manzi · Director
Mark Stevenson · EVP and COO
Mark Stevenson · EVP and COO
Stephen Williamson · SVP and CFO
Joseph R. Holmes · VP and Chief Accounting Officer
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Mark Stevenson · EVP and COO
Jim P Manzi · Director
Michel Lagarde · EVP
Michel Lagarde · EVP
Mark Stevenson · EVP and COO
Marc N Casper · Chair and CEO
Marc N Casper · Chair and CEO
Mark Stevenson · EVP and COO
Mark Stevenson · EVP and COO
Peter E Hornstra · VP and Chief Accounting Officer
Marc N Casper · Chair and CEO
Stephen Williamson · SVP and CFO
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It has strategic collaboration with genedrive plc to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.